Bloom Burton Comments on BioSyent Inc.’s FY2024 Earnings (CVE:RX)

BioSyent Inc. (CVE:RX) – Investment analysts at Bloom Burton boosted their FY2024 EPS estimates for shares of BioSyent in a research note issued to investors on Tuesday, May 21st. Bloom Burton analyst D. Martin now expects that the company will earn $0.55 per share for the year, up from their previous estimate of $0.47. The consensus estimate for BioSyent’s current full-year earnings is $0.47 per share. Bloom Burton also issued estimates for BioSyent’s FY2025 earnings at $0.63 EPS.

BioSyent (CVE:RX) last issued its earnings results on Wednesday, March 13th. The company reported C$0.12 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.17 by C($0.05). The company had revenue of C$8.27 million for the quarter, compared to the consensus estimate of C$8.80 million. BioSyent had a return on equity of 18.97% and a net margin of 20.45%.

BioSyent Price Performance

Shares of BioSyent stock opened at C$9.00 on Thursday. The firm has a market cap of C$104.31 million, a PE ratio of 16.98 and a beta of 0.93. The stock has a 50 day moving average of C$8.61 and a 200 day moving average of C$8.60. The company has a current ratio of 6.48, a quick ratio of 6.91 and a debt-to-equity ratio of 3.51. BioSyent has a 12 month low of C$7.03 and a 12 month high of C$9.26.

Insider Activity at BioSyent

In other BioSyent news, insider BioSyent Inc. purchased 5,100 shares of the stock in a transaction that occurred on Monday, April 29th. The stock was purchased at an average price of C$8.55 per share, with a total value of C$43,627.95. 38.45% of the stock is owned by insiders.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.